cached image

Darryle Schoepp

Affiliations: 
Merck Research Laboratories, Boston, MA, United States 
Area:
Glutamate
Google:
"Darryle Schoepp"
Mean distance: 17.87 (cluster 6)
 
SNBCP
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Feldman HH, Haas M, Gandy S, et al. (2014) Alzheimer's disease research and development: a call for a new research roadmap. Annals of the New York Academy of Sciences. 1313: 1-16
Wright RA, Johnson BG, Zhang C, et al. (2013) CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography. Neuropharmacology. 66: 89-98
Schoepp DD. (2011) Where will new neuroscience therapies come from? Nature Reviews. Drug Discovery. 10: 715-6
Javitt DC, Schoepp D, Kalivas PW, et al. (2011) Translating glutamate: from pathophysiology to treatment. Science Translational Medicine. 3: 102mr2
Nicoletti F, Bockaert J, Collingridge GL, et al. (2011) Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology. 60: 1017-41
Linden AM, Johnson BG, Trokovic N, et al. (2009) Use of MGLUR2 and MGLUR3 knockout mice to explore in vivo receptor specificity of the MGLUR2/3 selective antagonist LY341495. Neuropharmacology. 57: 172-82
Nicoletti F, Collingridge G, Schoepp D. (2008) 2008 Eruptions in metabotropic glutamate receptors Neuropharmacology. 55: 391
Fell MJ, Svensson KA, Johnson BG, et al. (2008) Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). The Journal of Pharmacology and Experimental Therapeutics. 326: 209-17
Conn PJ, Tamminga C, Schoepp DD, et al. (2008) Schizophrenia: moving beyond monoamine antagonists. Molecular Interventions. 8: 99-107
Dunayevich E, Erickson J, Levine L, et al. (2008) Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 1603-10
See more...